AI illustration · not actual product photoDetails from the source.
This catalogue entry records Selank, 5 mg × 10 vials (SKU SK5), using the supplied source listing. The cited dossier describes: Human studies have investigated Selank in generalized anxiety, neurasthenia, and phobic/anxiety and somatoform disorders. Laboratory and animal studies have examined biochemical, gene-expression, and behavioral effects. It also distinguishes available human evidence, limitations, safety concerns, and regulatory context. It does not verify this supplier-specific item’s identity, formulation, lot quality, or approval. This is not medical advice, a treatment recommendation, or authorization for human use.
- Catalogue code
- SK5
- Source specification
- 5mg*10vials
- Source document
- PriceList(1).pdf, page 1
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
Exact source listing label: Selank. Catalogue variants are SK5 — *10vials, price 43 per 10 vials; SK10 — *10vials, price 63 per 10 vials (currency not stated). Scientific literature describes Selank as a synthetic heptapeptide, but the catalogue provides no analytical evidence that these vials contain the same sequence or a particular salt/formulation.
Biological mechanism
The mechanism is not established. Proposed mechanisms include inhibition of enkephalin-degrading enzymes and modulation of GABAergic neurotransmission. Enkephalin-hydrolysis findings and rat gene-expression changes are mechanistic research, not proof of a human molecular target or clinical effect.
Research focus
Human studies have investigated Selank in generalized anxiety, neurasthenia, and phobic/anxiety and somatoform disorders. Laboratory and animal studies have examined biochemical, gene-expression, and behavioral effects. Animal combination findings, including Selank with diazepam, do not establish human combination effects.
Potential applications in the evidence
Anxiety-related conditions, including generalized anxiety and phobic/anxiety disorders, have been investigated in small human comparative reports. These are research areas, not established or approved uses; evidence does not support treatment or efficacy claims.
Human evidence
Two small Russian-language comparative clinical reports are indexed in PubMed: a 2008 study of 62 people with generalized anxiety disorder and neurasthenia (30 received Selank and 32 medazepam) and a 2014 report involving 60 people with phobic-anxiety and somatoform disorders. Their abstracts report anxiolytic observations but provide limited methodological detail, adverse-event counts, and long-term follow-up. They do not establish reliable effect size, uncommon risks, durability, or independently replicated efficacy.
Known and potential effects
The small clinical-report abstracts do not provide adequate adverse-event rates, so common or rare adverse effects cannot be reliably characterized. Lack of detailed reporting should not be interpreted as evidence of safety. FDA specifically notes potential immunogenicity concerns for compounded selank acetate for certain routes, related to possible aggregation and peptide-related impurities; this is a regulator concern, not proof that these listed vials are compounded or share a specific route or formulation.
Safety and contraindications
Long-term safety, contraindications, and the exact vial's identity, purity, sterility, route, excipients, and manufacturing controls cannot be verified from the supplied catalogue. FDA reports limited safety information for selank acetate and potential route-dependent immunogenicity concerns for compounded forms. No product-specific approved prescribing information was identified. Do not infer safety or suitability from the listing label.
U.S. FDA / regulatory status
FDA lists selank acetate in Category 2 of bulk drug substances nominated under sections 503A or 503B that may present significant safety risks for compounding. This is a compounding-review classification, not FDA approval and not evidence that the catalogue product is compounded. No FDA-approved Selank product or approval for these exact vials was identified in the official sources reviewed. The catalogue omits manufacturer, jurisdiction, formulation source, authorization number, approved label, and batch documentation; approval of an active ingredient or a specific branded formulation would not transfer to these unidentified vials. Global or exact-vial authorization cannot be verified.
Evidence limitations
Available evidence consists of small, older clinical reports with Russian-language abstracts and preclinical research. The evidence reviewed does not resolve study design quality, bias, reproducibility, comparative effectiveness, clinical significance, or comprehensive and long-term safety. Animal and cell findings must remain separate from human evidence. The catalogue label does not confirm the identity of the material used in published studies.
Supporting sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration · Official regulator safety / compounding information. Supports: FDA Category 2 context and Selank acetate concerns about potential route-dependent immunogenicity, aggregation, peptide-related impurities, and limited safety information; does not establish the status of the catalogue vials.
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia PubMed, U.S. National Library of Medicine · Primary comparative clinical study record. Supports: Human report: 62 patients with GAD/neurasthenia, comparison of Selank and medazepam, and limitations visible in the abstract.
- A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders PubMed, U.S. National Library of Medicine · Primary clinical study record. Supports: Human comparative clinical report on 60 patients with phobic-anxiety and somatoform disorders; limited abstract detail on design and adverse events.
- The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity PubMed, U.S. National Library of Medicine · Primary mechanistic study record. Supports: Proposed enkephalin-hydrolysis mechanism and reported plasma enzyme findings; not proof of a human clinical mechanism.
- Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission Frontiers in Pharmacology / PubMed Central, U.S. National Library of Medicine · Primary preclinical study. Supports: Published peptide sequence and diacetate salt for study material, rat gene-expression findings, and proposed GABA-related mechanism; does not verify catalogue vial identity.
- Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety-like Behavior under Conditions of Chronic Stress PubMed Central, U.S. National Library of Medicine · Primary animal study. Supports: Rat-only Selank/diazepam combination work and the animal-study boundary; no direct human combination evidence.
- Drugs@FDA: FDA-Approved Drugs U.S. Food and Drug Administration · Official regulatory database. Supports: Official Drugs@FDA database context and stated scope for FDA-approved drugs; does not by itself establish international or exact-vial status.